CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 54.3 USD 2.8%
Market Cap: 4.7B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+49%
Revenue
Forecast
+122%
Operating Income
Forecast
+9%
Net Income
Forecast
+6%

Wall Street
Price Targets

CRSP Price Targets Summary
CRISPR Therapeutics AG

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 81.06 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

CRSP Lowest Forecast
Wall Street Target
32.32 USD
40% Downside
CRSP Average Forecast
Wall Street Target
81.06 USD
49% Upside
CRSP Highest Forecast
Wall Street Target
281.4 USD
418% Upside
Lowest
Price Target
32.32 USD
40% Downside
Average
Price Target
81.06 USD
49% Upside
Highest
Price Target
281.4 USD
418% Upside
CRISPR Therapeutics AG Competitors:
Price Targets
H
301207
Hualan Biological Bacterin Inc
5% Upside
BEAM
Beam Therapeutics Inc
178% Upside
EDIT
Editas Medicine Inc
40% Upside
603087
Gan & Lee Pharmaceuticals
8% Downside
H
301207
Hualan Biological Bacterin Inc
5% Upside
BEAM
Beam Therapeutics Inc
178% Upside
EDIT
Editas Medicine Inc
40% Upside
603087
Gan & Lee Pharmaceuticals
8% Downside
K
4584
Kidswell Bio Corporation
82% Upside
688235
Beigene Ltd
30% Upside
E
206650
EuBiologics Co Ltd
43% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
27% Upside

Revenue
Forecast

Revenue Estimate
CRISPR Therapeutics AG

For the last 9 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 79%. The projected CAGR for the next 3 years is 122%.

79%
Past Growth
122%
Estimated Growth
Estimates Accuracy
13%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss
What are analyst estimates?

See Also

Summary
CRSP intrinsic value, competitors valuation, and company profile.
DCF Valuation
CRSP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CRSP stock valuation using valuation multiples.
Wall Street Estimates
CRSP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CRSP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CRSP's stock price target?
Price Target
81.06 USD

According to Wall Street analysts, the average 1-year price target for CRSP is 81.06 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

What is CRISPR Therapeutics AG's Revenue forecast?
Projected CAGR
122%

For the last 9 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 79%. The projected CAGR for the next 3 years is 122%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 277,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.